Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 8/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | HRH2 | P25021 | 3/20 | 0.38 |
| ▸ | HRH4 | Q9H3N8 | 3/20 | 0.38 |
| ▸ | REN | P00797 | 2/20 | 0.38 |
| ▸ | HRH1 | P35367 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.37 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.37 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18857595 | 0.81 | REN (0.47) | HRH3CYP3A4CYP2D6TSHRCYP2C19 | |
| SCHEMBL15257835 | 0.77 | QPCT (0.46) | HRH3CYP3A4CYP2D6TSHRCYP2C19 | |
| SCHEMBL18862360 | 0.77 | REN (0.52) | HRH3CYP3A4CYP2D6TSHRCYP2C19 | |
| SCHEMBL1688304 | 0.77 | QPCT (0.47) | HRH3CYP3A4CYP2D6TSHRCYP2C19 | |
| SCHEMBL15259282 | 0.75 | QPCT (0.54) | HRH3CYP3A4CYP2D6TSHRCYP2C19 | |
| SCHEMBL23733388 | 0.73 | QPCT (0.48) | HRH3CYP3A4CYP2D6TSHRCYP2C19 | |
| SCHEMBL14725175 | 0.71 | QPCT (0.44) | HRH3CYP3A4CYP2D6TSHRCYP2C19 | |
| SCHEMBL18862090 | 0.71 | CYP3A4 (0.50) | HRH3CYP3A4CYP2D6TSHRCYP2C19 | |
| SCHEMBL15185921 | 0.70 | CYP3A4 (0.49) | HRH3CYP3A4CYP2D6TSHRCYP2C19 | |
| SCHEMBL17040361 | 0.68 | QPCT (0.48) | HRH3CYP3A4CYP2D6TSHRCYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150344540-A1 | NOVEL GLP-1 RECEPTOR AGONISTS WITH CHOLESTEROL EFFLUX ACTIVITY | NOVO NORDISK A/S (DK) | 2015-12-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150344540-A1 | NOVEL GLP-1 RECEPTOR AGONISTS WITH CHOLESTEROL EFFLUX ACTIVITY | GLP1R, GIPR, GCGR | HRH3 2845/4885CYP3A4 2108/4885CYP2D6 3132/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.